Braver Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Braver Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,400	Closed	-$505K	–	151
2016 Q1	$505K	Buy	+1,400	New	+$577K	0.08%	105
2015 Q3	–	Sell	-1,400	Closed	-$714K	–	90
2015 Q2	$714K	Hold	1,400	–	–	0.17%	65
2015 Q1	$632K	Hold	1,400	–	–	0.13%	69
2014 Q4	$374K	Buy	+1,400	New	+$551K	0.08%	71
2014 Q3	–	Sell	-1,400	Closed	-$395K	–	86
2014 Q2	$395K	Hold	1,400	–	–	0.1%	72
2014 Q1	$420K	Hold	1,400	–	–	0.12%	61
2013 Q4	$385K	Hold	1,400	–	–	0.13%	63
2013 Q3	$438K	Hold	1,400	–	–	0.15%	66
2013 Q2	$315K	Buy	+1,400	New	+$326K	0.14%	58

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Braver Wealth Management's REGN Position: Q2 2016 in Review

Braver Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 1,400 shares — an estimated $505K sold.

Braver Wealth Management first reported a position in REGN in Q2 2013 and held it in 9 quarters. The position peaked at $714K in Q2 2015. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

Braver Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Braver Wealth Management sold 1,400 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $505K.
Braver Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Braver Wealth Management's Regeneron Pharmaceuticals position peaked at $714K in Q2 2015.
542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Braver Wealth Management's 13F filing for Q2 2016, filed 13 Jul 2016.